[ET Net News Agency, 9 August 2019] HSBC Global Research lifted its target price for PA
Good Doctor (PAGD)(01833) to HK$57.3 from HK$55.5 and maintained its "buy" rating.
The research house said PAGD's revenue in achieved 50% of HSBC's full-year estimate
despite consumer healthcare revenue tending to be lower as it can only be recognised after
the performance of underlying services.
In June, the State Council promulgated the Key Tasks for Deepening the Reform of the
Medical and Healthcare System. Management is embracing the favourable regulatory backdrop
and expanding its client acquisition channels. It also enhanced opportunities for
corporate collaboration such as the newly announced partnership with China Mobile (00941)
and other insurance providers. (KL)